1477. A Randomized Phase 2 Study of Cefepime Combined with the Novel Extended Spectrum β-Lactamase Inhibitor Enmetazobactam in Hospitalized Adults with Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP)

BACKGROUND: Third-generation cephalosporin (3GC)-resistant Enterobacteriaceae has been classified as critical priority pathogens. The novel extended-spectrum β-lactamase (ESBL) inhibitor enmetazobactam (formerly AAI101; EMT) in combination with cefepime (FEP) is currently being developed as a carbap...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmeli, Yehuda, Knechtle, Philipp, Hardenberg, Jeff, Knecht, Mathias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809748/
http://dx.doi.org/10.1093/ofid/ofz360.1341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809748/
http://dx.doi.org/10.1093/ofid/ofz360.1341

Ejemplares similares